logo
Korea challenged as Asia's rising art hub beset by uncertainties, weak Korean won

Korea challenged as Asia's rising art hub beset by uncertainties, weak Korean won

Korea Herald12-02-2025
December martial law final blow to already troubled art scene
The Korean art scene has been upbeat in the past few years, rising as an art hub in Asia with international galleries setting up here and Frieze Seoul launching in 2022. Now, the city's once-vibrant art scene faces multiple challenges as political uncertainties continue.
The heyday of the Korean art market came in 2021, when market transactions reached 756.3 billion won ($520.5 million), a 96 percent increase from the previous year. It reached its peak the following year, with the market worth an unprecedented 806.6 billion won, according to the Korea Arts Management Service's annual reports.
This was when international galleries began opening in the city, whose arrival coincided with the inauguration of Frieze Seoul.
The festive mood in Seoul was short-lived, however. In 2023, the art market began declining. That year saw 692.8 billion won in market transactions as the market responded to the economic downturn. Last year was even worse with successful bids at the country's leading auction houses falling 25.2 percent on-year, according to Korea Art Authentication Appraisal Inc. figures.
The declaration of martial law on Dec. 3 was the final blow. The hours-long martial law imposition is having a lasting effect, freezing the art market as the won declined sharply against the dollar to hover around the 1,400-won level.
The martial law was like 'pouring cold water' on the bearish Korean art market, multiple gallerists said.
'It seems things have been put on hold at many galleries -- no investment and no events. We are staying low key,' said a gallerist in Seoul on condition of anonymity.
Selection Seoul, a new art fair originally slated for a spring launch, saw its opening postponed to next year due to the weak won and declining consumer sentiment. Selection Seoul Director Kim Jyeong-yeon said that among the variables she took into account in preparing for the fair, martial law was beyond 'her imagination.'
Martial law was the "trigger" that stopped everything, according to Kim. 'You know, the market was bearable before this happened. But now, the exchange rate has become a huge problem in terms of sales and shipping," she said. "We can't persuade Korean collectors at this exchange rate to buy art," she added.
She also noted that sponsors have also turned "passive," unwilling to take risks. "Hopefully, things will be better by next year,' she said.
When martial law was declared, Director Lee Joon-yub of Gallery Shilla, had to push back an exhibition of old masters as the artists expressed anxiety.
'As a young generation, we have no experience in such a thing. We learned what martial law was only from history textbooks, (it) happened in our parents' generation,' the 35-year-old director of the Daegu-based gallery said. 'But the older artists, who experienced martial law in the 1970s and 1980s, seemed really worried and wanted to call off the plan for an exhibition," Lee said.
Recent tariff threats by US President Donald Trump have worsened consumer sentiment and weakened the Korean won against the dollar, which all work against Korea's art market.
Weak Korean won pressures international galleries
The continuing depreciation of the Korean won has hit international galleries harder as many of the artworks handled by international galleries are priced in foreign currencies. This has led to a 10-20 percent rise in the price of artwork for domestic collectors and a hike in shipping fees for exhibitions.
Between 2021 and 2023, several large international galleries set up shop in Seoul, attracted by the city's vibrant culture scene, younger collectors and a favorable tax system.
When European gallery Thaddaeus Ropac arrived in the city in October 2021, the Korean won-dollar rate was below 1,250 won to a dollar.
'The economic sentiment is not quite as good these days. Collectors are taking longer than usual to decide to buy artwork,' said Hwang Kyu-jin, the gallery's executive director in Seoul.
'The exchange rate fluctuated and moved to the 1,300-level last year, but we expected the exchange rate to settle down at some point soon. But, for now, it seems it will take longer."
Lee Young-joo, senior vice president and director of Pace Gallery in Seoul, said the purchasing power of big collectors fell strikingly starting last year, following an economic downturn.
The US gallery opened its Seoul venue in 2017 and expanded to the current 790-square-meter space in Hannam-dong in 2022.
'Economic uncertainty seems to cause people to push back purchasing art,' she said. 'What is more, the strong dollar against the won has raised the price of works traded in dollars, worsening the consumer sentiment," she said, adding buyers request large discounts to offset the rise in price caused by the weak won.
White Cube Seoul arrived in Seoul in 2023 as White Cube's second permanent gallery in Asia. The gallery said it is 'proactively' seeking solutions following the depreciation of the Korean won.
'The depreciation of the Korean won has indeed had a significant impact, especially on our domestic clients,' said Jini Yang, director of White Cube Seoul. 'But we remain hopeful for a prompt stabilization of both domestic and international condition.'
As a pioneering international gallery in the city, Lehmann Maupin in Seoul, launched in 2017, has witnessed the up-and-downs in the city's art scene, said Senior Director Emma Son. The 'exponentially' increased cost of shipping artworks this year due to the exchange rate has become a huge burden for the gallery, she noted.
'It is not just for Korea, the global art scene constantly goes through political and economic challenges. I think it is important to take a broader perspective and hold on to the belief that art has its role in the complex world.
"Things will pass for sure, and we will turn it to our advantage, taking time to figure out how we can operate the gallery in Seoul more efficiently,' she said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AMI Launches Developer Program for Arm Total Design to Rapidly Accelerate Arm-based Chiplet Development
AMI Launches Developer Program for Arm Total Design to Rapidly Accelerate Arm-based Chiplet Development

Korea Herald

time2 hours ago

  • Korea Herald

AMI Launches Developer Program for Arm Total Design to Rapidly Accelerate Arm-based Chiplet Development

ATLANTA, Aug. 12, 2025 /PRNewswire/ -- AMI® is proud to announce the AMI Developer Program for Arm® Total Design, specifically designed to enable Arm Total Design ecosystem partners to streamline the process of developing, testing, validating, and hardening custom silicon, including chiplets, powered by Arm Neoverse™ Compute Subsystems (CSS). Additionally, the program offers a simpler, more cost-effective pathway for the Arm Total Design ecosystem to transform their unique designs into market-ready products. Sanjoy Maity, CEO of AMI, stated that, "Our goal with this new program is to ensure silicon designers get full access to necessary firmware technology and IP blocks that help them bring Arm-based custom silicon to life and fine tune their products very quickly, while still allowing them to remain within their project budget. By leveraging AMI firmware products, together with the benefits of Arm Total Design, we aim to help the ecosystem rapidly arrive at their point of commercialization." Srivatsan Ramachandran, SVP of Strategic Partnerships at AMI, noted, "The AMI Developer Program for Arm Total Design brings together custom silicon designs, dynamic firmware, and advanced ecosystem partner technologies in a rapid and collaborative way to shift-left Arm-based custom silicon designs. Most importantly, the Developer Program will eliminate many of the roadblocks faced by a traditional commercial engagement, facilitating smoother and quicker entry into the design process." The AMI Developer Program for Arm Total Design features generous licensing terms for our Exclusive and Early Adopter Partners for AMI firmware solutions like OpenBMC™-based MegaRAC OneTree™ Manageability Firmware and Aptio® V UEFI Firmware, and much more. Contact AMI or visit our website for more details on the complete terms and conditions of the Developer Program, the benefits of working with AMI, and to get started on your Arm Neoverse CSS-based chiplet design journey today. Arm and Neoverse are registered trademarks and trademarks of Arm Limited (or its subsidiaries or affiliates) in the US and/or elsewhere. Aptio and MegaRAC are registered trademarks of AMI US Holdings, Inc. OpenBMC is a trademark of LF Projects, LLC. All other registered trademarks and trademarks are the property of their respective companies. About AMI AMI is Firmware Reimagined for modern computing. As a global leader in Dynamic Firmware for security, orchestration, and manageability solutions, AMI enables the world's compute platforms from on-premises to the cloud to the edge. AMI's industry-leading foundational technology and unwavering customer support have generated lasting partnerships and spurred innovation for some of the most prominent brands in the high-tech industry.

National security adviser meets visiting US representatives ahead of Lee-Trump summit
National security adviser meets visiting US representatives ahead of Lee-Trump summit

Korea Herald

time7 hours ago

  • Korea Herald

National security adviser meets visiting US representatives ahead of Lee-Trump summit

National Security Adviser Wi Sung-lak met with two visiting US Representatives on Tuesday and discussed ways to bolster industrial cooperation and the alliance between the two nations, the presidential office said. Wi met Rep. Beth Van Duyne and Rep. Richard McCormick, as President Lee Jae Myung is preparing to hold his first summit with US President Donald Trump in Washington on Aug. 25. He highlighted that Korean companies have been investing in strategic sectors, such as semiconductors and automotive batteries, in their districts of Texas and Georgia, asking for their support to further advance the bilateral alliance and industrial cooperation for "win-win" outcomes, the office said in a release. Samsung Electronics has been building a new semiconductor manufacturing facility in Taylor, Texas. Hyundai Motor Group is constructing a new electric vehicle plant in Georgia and partnering with Korean battery maker SK On to build a battery plant there, in addition to SK On's two battery plants in the state. Wi expressed his expectation that Lee and Trump will reaffirm the strong alliance and have in-depth discussions on ways to advance it, and the two lawmakers pledged their full support for a successful summit, the office said. Van Duyne and McCormick also promised to support further US investments by Korean companies to strengthen economic cooperation and pledged to work together for bipartisan support in Congress for the Korea-US alliance, it noted. (Yonhap)

Intas & Accord signs Agreement to acquire Prothya Biosolutions
Intas & Accord signs Agreement to acquire Prothya Biosolutions

Korea Herald

time7 hours ago

  • Korea Herald

Intas & Accord signs Agreement to acquire Prothya Biosolutions

AHMEDABAD, India, Aug. 11, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leading plasma-derived medicinal products (PDMP) business based primarily in the Netherlands and Belgium. Subject to the satisfaction of customary closing conditions, including regulatory clearances, the deal is anticipated to close shortly. This proposed acquisition marks a significant step in Intas and Accord's long-standing ambition to establish a global presence in the PDMP market, expanding Intas's established leadership in India into a truly international footprint. Prothya Biosolutions, with primary operations in Amsterdam and Brussels and plasma collection centres across Hungary, employs approximately 1,200 people. The company is one of Europe's largest plasma fractionators. Formed in 2021 through the integration of Plasma Industries Belgium, originally linked to the Belgian Red Cross, and Sanquin Plasma Products, formerly a part of the Sanquin Blood Supply Foundation, Prothya brings over 60 years of experience in plasma collection and the development of PDMPs. Binish Chudgar, Chairman of Intas & Accord, stated: "We are delighted to expand our plasma business through the acquisition of Prothya Biosolutions. Combined with our fractionation capabilities in India, this positions us to create a truly global plasma platform—serving patients worldwide with critical, often under-prescribed, therapies." Intas's plasma division in India has been supplying hospitals with PDMPs since 2015, supported by an annual fractionation capacity of over 1 million litres and exports to multiple international markets. Additional capacity is due to come online with the expansion of Intas's Gujarat-based facility. Nir Epstein, CEO of Prothya, commented: "Over the past four years, we've expanded into new markets, advanced critical therapies, established our own plasma collection network in Hungary, and supplied plasma derivatives to some of the world's leading PDMP companies—all while building a stronger, more resilient organization. I want to thank our dedicated team for their unwavering commitment to our patients. I believe Accord is the right company to support Prothya and its people in the next phase of growth and global expansion." The global market for PDMPs—particularly IVIG (intravenous immunoglobulin)—is currently valued at $30 billion and is expected to reach $50 billion by 2035. This acquisition will give Intas access to significant additional fractionation capacity, supported by Accord's commercial footprint spanning 85 countries. BofA Securities is acting as the exclusive financial advisor to Accord in this transaction. Evercore is acting as the exclusive financial advisor to Prothya in this transaction. About Intas: Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad, India, having end-to-end capabilities of formulation development, manufacturing, and marketing along with backward integration of APIs. Intas also has strong in-house biosimilar development and marketing capabilities, with more than 15 products being marketed. Intas is committed to expanding global healthcare access by providing affordable, high-quality medications through strategic partnerships and extensive R&D investment to meet the diverse needs of healthcare systems around the world. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare, to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Asia-Pacific as well as CIS and MENA countries. Intas's remarkable success in North America and European operations has helped us emerge as a global brand in the world's largest pharmaceutical markets.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store